- Question from AngieInCO: Can you tell me anything about the new drug everolimus?
- Answers - Andrew D. Seidman, M.D. Everolimus and temsirolimus (brand name: Torisel) are agents in a new class of drugs known as mTOR inhibitors. mTor is a molecule that is part of the cell's wiring to transmit signals and allow cancer cells to proliferate and behave badly. Everolimus is an agent that blocks this signaling pathway and is currently in Phase II and III clinical trials for metastatic breast cancer. It has already been approved for use in other types of cancer.
On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.